Androgen receptor splice variant V7 (AR-V7) in circulating tumor cells: A coming of age for AR splice variants?

Annals of Oncology

Volumn 26, Issue 9, 2015, Pages 1805-1807

  Sprenger, C ^a   Uo, T ^a   Plymate, S ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ANDROGEN RECEPTOR; BIOLOGICAL MARKER; DOCETAXEL; ENZALUTAMIDE; PROSTATE SPECIFIC ANTIGEN; TAXANE DERIVATIVE; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; AR PROTEIN, HUMAN; ISOPROTEIN; PHENYLTHIOHYDANTOIN; TUMOR MARKER;

ANDROGEN DEPRIVATION THERAPY; AR V7 GENE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CIRCULATING TUMOR CELL; DISEASE MARKER; DOWN REGULATION; EDITORIAL; GENE; GENE EXPRESSION; GENETIC VARIABILITY; HORMONAL REGULATION; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; GENETICS; MALE; PATHOLOGY; PROSTATIC NEOPLASMS; TREATMENT OUTCOME; TUMOR EMBOLISM; TUMOR RECURRENCE;

ANDROSTENES; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC CELLS, CIRCULATING; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; RECEPTORS, ANDROGEN; TREATMENT OUTCOME;

EID: 84941645073     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv311     Document Type: Editorial

References (12)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Chen CD, Welsbie DS, Tran C et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10: 33-39.
3. Cooperberg MR, Hinotsu S, Namiki M et al. Trans-Pacific variation in outcomes for men treated with primary androgen-deprivation therapy (ADT) for prostate cancer. BJU Int 2014 Sep 19 [epub ahead of print], doi: 10.1111/bju.12937.
4. Samson DJ, Seidenfeld J, Schmitt B et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 2002; 95: 361-376.
5. Huggins C. Effect of orchiectomy and irradiation on cancer of the prostate. Ann Surg 1942; 115: 1192-1200.
6. James ND, Spears MR, Clarke NW et al. Survival with newly diagnosed metastatic prostate cancer in the "Docetaxel Era": data from 917 patients in the control arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). Eur Urol 2015; 67: 1028-1038.
7. Sprenger CC, Plymate SR. The link between androgen receptor splice variants and castration-resistant prostate cancer. Horm Cancer 2014; 5: 207-217.
8. Antonarakis ES, Lu C, Wang H et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014; 371: 1028-1038.
9. Nakazawa M, Lu C, Chen Y et al. Serial blood-based analysis of AR-V7 in men with advanced prostate cancer. Ann Oncol 2015; 26: 1859-1865.
10. Thadani-Mulero M, Portella L, Sun S et al. Androgen receptor splice variants determine taxane sensitivity in prostate cancer. Cancer Res 2014; 74: 2270-2282.
11. Reid AH, Attard G, Danila DC et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010; 28: 1489-1495.
12. Schweizer MT, Antonarakis ES, Wang H et al. Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study. Sci Transl Med 2015; 7: 269ra2.